The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Using G100 (Glucopyranosyl Lipid A) to transform the sarcoma tumor immune microenvironment.
 
Seth Pollack
No Relationships to Disclose
 
Edward Y. Kim
No Relationships to Disclose
 
Ernest U. Conrad
No Relationships to Disclose
 
Ryan Blair O'Malley
No Relationships to Disclose
 
Sara Cooper
No Relationships to Disclose
 
Bailey Donahue
No Relationships to Disclose
 
Lee D. Cranmer
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - Amgen; Bristol-Myers Squibb; CytRx Corporation; GlaxoSmithKline; Merck; Prometheus; Threshold Pharmaceuticals
 
Hailing Lu
Employment - Immune Design
Stock and Other Ownership Interests - Immune Design
 
Elizabeth Trice Loggers
No Relationships to Disclose
 
Tailor Hain
No Relationships to Disclose
 
Darin J Davidson
No Relationships to Disclose
 
Lynn Bonham
No Relationships to Disclose
 
Venu Gopal Pillarisetty
No Relationships to Disclose
 
Gabrielle Kane
No Relationships to Disclose
 
Stanley R. Riddell
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Adaptive Biotechnologies; Cell Medica; Juno Therapeutics
Research Funding - Juno Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Robin Lewis Jones
Honoraria - Compass Oncology; EMD Serono; IMS Health; Novartis; Pfizer; The Dominion Group
Consulting or Advisory Role - Compass Oncology; EMD Serono; IMS Health; Novartis; Pfizer; The Dominion Group
Research Funding - Bayer (Inst); Eisai (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); MabVax (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Novartis (Inst); PharmaMar (Inst); Threshold Pharmaceuticals (Inst); Ziopharm Oncology (Inst)
Travel, Accommodations, Expenses - Compass Oncology; EMD Serono; Novartis; Pfizer; PharmaMar